TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9865705

Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2 every 3 weeks
Number of subjects: 326

Group type: COMPARATOR
Intervention: Doxorubicin 75 mg/m2 every 3 weeks
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Docetaxel in patients with resistant disease
Number of subjects: 326

Group type: COMPARATOR
Intervention: Doxorubicin in patients with resistant disease
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 326

Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 326
Study: 7613277

Group type: EXPERIMENTAL
Intervention: Homoeopathy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2136976

Group type: EXPERIMENTAL
Intervention: Fentanyl (1.0, 2.0, and 4.0 micrograms/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sufentanil (0.1, 0.2, and 0.4 micrograms/kg)
Number of subjects: 30
Study: 109635

Group type: EXPERIMENTAL
Intervention: High nitrogen elemental diet (300 calories tid)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard diet with usual between‐meal feedings
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nutritionally supported patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 6295270

Group type: EXPERIMENTAL
Intervention: Ceftizoxime 2, 3, or 4 g intravenously
Number of subjects: 13
Study: 31881916

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control (psycho-education and relaxation)
Number of subjects: 94
Study: 29595707

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Naloxone (0.15 mg/kg bolus dose, then 0.2 mg/kg per hour infusion)
Number of subjects: 32
Study: 26697854

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 24622715

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 22498663

Group type: EXPERIMENTAL
Intervention: Peripheral sensory nerve stimulation combined with task-oriented training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Task-oriented training alone
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study: 20079168

Group type: EXPERIMENTAL
Intervention: CT scanning with 16 x 1.25 mm collimation and a 70 ml contrast injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: CT with 64 x 0.625 mm collimation and 20 ml of contrast injection
Number of subjects: 40
Study: 17621601

Group type: EXPERIMENTAL
Intervention: Desflurane 6% for 30 min
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sevoflurane 2% for 30 min
Number of subjects: 28
Study: 16306539

Group type: EXPERIMENTAL
Intervention: Diabetes case management
Number of subjects: 149

Group type: COMPARATOR
Intervention: Traditional treatment (Control)
Number of subjects: 149
Study: 12220942

Group type: EXPERIMENTAL
Intervention: Formoterol Turbuhaler 6 microg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Formoterol Aerolizer 12 microg
Number of subjects: 16
Study: 9620514

Group type: EXPERIMENTAL
Intervention: Ketamine 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alfentanil 2 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ketamine 10 mg + Alfentanil 1 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ketamine 2.5 mg + Alfentanil 0.25 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ketamine 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alfentanil 0.5 mg
Number of subjects: 12
Study: 7695320

Group type: EXPERIMENTAL
Intervention: Amikacin once daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Amikacin twice daily
Number of subjects: 10
Study: 2785234

Group type: EXPERIMENTAL
Intervention: multidose cardioplegia
Number of subjects: 20

Group type: COMPARATOR
Intervention: single-dose cardioplegia with a cooling jacket
Number of subjects: 20
Study: 562092

Group type: EXPERIMENTAL
Intervention: Droperidol (5 mg)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Diphenidol (40 mg)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo (2 ml of 0.9% saline)
Number of subjects: 210
Study: 31947813

Group type: EXPERIMENTAL
Intervention: Both-parent migration
Number of subjects: 0
Study: 31155692

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 134
Study: 26377300

Group type: EXPERIMENTAL
Intervention: Ofatumumab maintenance treatment (300 mg followed by 1000 mg 1 week later and every 8 weeks for up to 2 years)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Ofatumumab maintenance treatment
Number of subjects: 474
Study: 23860722

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 3041

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3041

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3041
Study: 21306322

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with intrathecal morphine (SA)
Number of subjects: 162

Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 162
Study: 19254583

Group type: EXPERIMENTAL
Intervention: Rescue steroid group (betamethasone, 2 12‐mg doses 24 hours apart)
Number of subjects: 437

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 437
Study: 16778261

Group type: EXPERIMENTAL
Intervention: Training by a housestaff team
Number of subjects: 49

Group type: COMPARATOR
Intervention: Training by a single experienced teaching attending
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Scenario-based simulation training (SST)
Number of subjects: 49
Study: 15046541

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Citalopram (active comparator for escitalopram)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluoxetine (active comparator for duloxetine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paroxetine (active comparator for duloxetine)
Number of subjects: 0
Study: 11932134

Group type: EXPERIMENTAL
Intervention: Behavioral Couples Therapy (BCT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Individual-based treatment (IBT)
Number of subjects: 80
Study: 9614604

Group type: EXPERIMENTAL
Intervention: Nutrition curriculum
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Standard curriculum
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Choice condition
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Attendance in either curriculum
Number of subjects: 596

Group type: COMPARATOR
Intervention: No choice condition
Number of subjects: 596
Study: 7649691

Group type: EXPERIMENTAL
Intervention: Cemented PCA modular cruciform‐stemmed tibial components
Number of subjects: 26

Group type: COMPARATOR
Intervention: Uncemented PCA modular cruciform‐stemmed tibial components
Number of subjects: 26
Study: 2798991

Group type: EXPERIMENTAL
Intervention: Benzodiazepines (BZ)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Benzodiazepines (BZ) plus Levodropropizine
Number of subjects: 5

Group type: COMPARATOR
Intervention: Levodropropizine
Number of subjects: 5
Study: 29441

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1 mg)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Nitrazepam (5 mg)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo (one tablet)
Number of subjects: 117
Study: 31147486

Group type: EXPERIMENTAL
Intervention: The Reading House (TRH)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Get Ready to Read! (GRTR)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Parent, child, and provider impressions of TRH
Number of subjects: 278
Study: 28466022

Group type: EXPERIMENTAL
Intervention: In-plane injection
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Out-of-plane injection
Number of subjects: 46
Study: 27004917

Group type: EXPERIMENTAL
Intervention: Fibrinogen 3g infusion
Number of subjects: 412

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 412
Study: 25073431

Group type: EXPERIMENTAL
Intervention: ECT
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ECT + AET
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: AET
Number of subjects: 60
Study: 22206074

Group type: EXPERIMENTAL
Intervention: Galvanic zinc-copper complex
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 19712040

Group type: EXPERIMENTAL
Intervention: Whole-virus H5N1 clade 1 A/Vietnam vaccine (2-dose priming regimen)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: 7.5-microg dose of a clade 2.1 A/Indonesia vaccine (booster)
Number of subjects: 141
Study: 17513402

Group type: EXPERIMENTAL
Intervention: Gamma-linolenate (GLA) 890 mg/d (5 g/d borage oil)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Olive oil (5 g/d)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gamma-linolenate (GLA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Olive oil (Control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: GLA-GLA (subgroup continued GLA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control-GLA (subgroup crossed over to GLA)
Number of subjects: 50
Study: 14701773

Group type: EXPERIMENTAL
Intervention: PS‐341 1.5 mg/m(2) administered intravenously twice weekly for 2 weeks every 21 days, with dose escalation to 1.7 mg/m(2) in absence of grade 3 to 4 toxicities.
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 23
Study: 11181998

Group type: EXPERIMENTAL
Intervention: vinorelbine/cisplatin
Number of subjects: 612

Group type: COMPARATOR
Intervention: vindesine/cisplatin
Number of subjects: 612

Group type: COMPARATOR
Intervention: vinorelbine alone
Number of subjects: 612
Study: 9441058

Group type: EXPERIMENTAL
Intervention: 6-month short-course chemotherapy regimen (SCC) with rifampicin, isoniazid and pyrazinamide for 2 months followed by rifampicin with isoniazid for another 4 months (6R series)
Number of subjects: 193

Group type: COMPARATOR
Intervention: 12-month standard regimen of ethambutol and isoniazid with streptomycin supplemented for 2 weeks (12E series)
Number of subjects: 193
Study: 7951290

Group type: EXPERIMENTAL
Intervention: Contract-relax treatment
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Leg pull treatment
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (supine quietly for 5 minutes)
Number of subjects: 75
Study: 3108930

Group type: EXPERIMENTAL
Intervention: L-deprenyl 10 mg/day
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: L-deprenyl 40 mg/day
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 29966958

Group type: EXPERIMENTAL
Intervention: Supplemental heat wrap therapy
Number of subjects: 176

Group type: COMPARATOR
Intervention: Multimodal treatment without supplemental heat wrap therapy
Number of subjects: 176
Study: 27052212

Group type: EXPERIMENTAL
Intervention: Clinical medication review followed by a pharmaceutical care plan
Number of subjects: 512

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 512
Study: 24513614

Group type: EXPERIMENTAL
Intervention: Thermogenic nutritional supplement
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 22088165

Group type: EXPERIMENTAL
Intervention: In-home interdisciplinary care management intervention combining palliative care and geriatric medicine approaches.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 80
Study: 20736149

Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 721

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 721
Study: 18416470

Group type: EXPERIMENTAL
Intervention: lafutidine 10 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: LPZ 30 mg
Number of subjects: 10
Study: 15641907

Group type: EXPERIMENTAL
Intervention: Inference learning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classification learning
Number of subjects: 0
Study: 12777162

Group type: EXPERIMENTAL
Intervention: Neptune Krill Oil (NKO)
Number of subjects: 70

Group type: COMPARATOR
Intervention: omega‐3 fish oil
Number of subjects: 70
Study: 11383262

Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 118

Group type: COMPARATOR
Intervention: Splint therapy
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Occlusal adjustment therapy
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Combination of splint and occlusal adjustment therapy
Number of subjects: 118
Study: 8878139

Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAA)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Flavored water (placebo)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: BCAA
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 1283584

Group type: EXPERIMENTAL
Intervention: Verapamil or Enalapril
Number of subjects: 27

Group type: COMPARATOR
Intervention: Atrial pacing
Number of subjects: 27

Group type: COMPARATOR
Intervention: Dipyridamole infusion
Number of subjects: 27
Study: 3862151

Group type: EXPERIMENTAL
Intervention: Amphetamine 30 mg, p.o.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 8
Study: 30009752

Group type: EXPERIMENTAL
Intervention: Collaborative Care Skills Training Workshops (CCSTW)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Psycho-educational programme
Number of subjects: 64
Study: 26036190

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) with aspirin
Number of subjects: 139

Group type: COMPARATOR
Intervention: Aspirin only
Number of subjects: 139
Study: 26323997

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 60 μg/week
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 120 μg/week
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 240 μg/week
Number of subjects: 50
Study: 23922479

Group type: EXPERIMENTAL
Intervention: Stepwise sedation (group Cs)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Continuous sedation (group Cc)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Stepwise sedation (group Ns)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Continuous sedation (group Nc)
Number of subjects: 86
Study: 21383847

Group type: EXPERIMENTAL
Intervention: Rubber right hand placed beside the real hand
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Questionnaire data and physiological evidence from skin conductance responses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conditions for elicitation of the supernumerary hand illusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparison with traditional rubber hand illusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artificial hand's effect on multisensory processes
Number of subjects: 0
Study: 18771838

Group type: EXPERIMENTAL
Intervention: One-visit root canal treatment
Number of subjects: 121

Group type: COMPARATOR
Intervention: Two-visit root canal treatment
Number of subjects: 121
Study: 16303215

Group type: EXPERIMENTAL
Intervention: Single nasal dose of vaccine containing 15, 30, or 45 microg of each of the three HA antigens
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Two nasal doses containing 30 microg of each HA, separated by 2 weeks
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Vaccine (all doses)
Number of subjects: 78
Study: 14998054

Group type: EXPERIMENTAL
Intervention: Ear acupuncture points (EAP) detection during orthopedic surgery
Number of subjects: 25

Group type: COMPARATOR
Intervention: Ear acupuncture points (EAP) detection in patients
Number of subjects: 25
Study: 10957689

Group type: EXPERIMENTAL
Intervention: Comprehensive hypertension care program; details on dosage and duration not available.
Number of subjects: 0
Study: 8836865

Group type: EXPERIMENTAL
Intervention: 100 mg alternate day oral aspirin (regular formulation)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 100 mg alternate day oral aspirin (enteric coated formulation)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 1445490

Group type: EXPERIMENTAL
Intervention: Probucol (250 mg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 3918688

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg daily
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Omeprazole 30 mg daily
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg daily (in smokers)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Omeprazole 30 mg daily (in smokers)
Number of subjects: 66
Study: 31504974

Group type: EXPERIMENTAL
Intervention: Brief, one-on-one, telephone-adapted mindfulness-based stress reduction (MBSR) intervention, 3 sessions
Number of subjects: 70

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 70
Study: 30099318

Group type: EXPERIMENTAL
Intervention: Breath-focused practice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Movement-focused practice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 27592123

Group type: EXPERIMENTAL
Intervention: TAU+MBCT-S (n=82)
Number of subjects: 164

Group type: COMPARATOR
Intervention: TAU (n=82)
Number of subjects: 164
Study: 24548425

Group type: EXPERIMENTAL
Intervention: Subcutaneous rFeIFN‐ω (Virbagen® omega, Virbac, Carros, France) administered via eight injections over four months.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Oral rFeIFN‐ω administered daily.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (subcutaneous rFeIFN‐ω).
Number of subjects: 26
Study: 21436164

Group type: EXPERIMENTAL
Intervention: Ibandronate (3 mg intravenous single dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 19473824

Group type: COMPARATOR
Intervention: CHO-Meal (control-meal plus 45 g carbohydrates)
Number of subjects: 11

Group type: COMPARATOR
Intervention: PRO-Meal (control-meal plus 45 g of casein)
Number of subjects: 11

Group type: COMPARATOR
Intervention: CHO+PRO-Meal (PRO-meal plus 45 g carbohydrates)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: CHO-Meal (control-meal plus 45 g carbohydrates) with casein added
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: PRO+CHO-Meal (PRO-meal plus 45 g carbohydrates)
Number of subjects: 11
Study: 17357131

Group type: EXPERIMENTAL
Intervention: Parkinson's disease patients
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 101
Study: 15572275

Group type: EXPERIMENTAL
Intervention: Risperidone (0.5 mg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 12233993

Group type: EXPERIMENTAL
Intervention: Cocaine-dependent outpatients (treatment group)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Cocaine-dependent outpatients (female participants)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Cocaine-dependent outpatients (male participants)
Number of subjects: 188
Study: 10087080

Group type: EXPERIMENTAL
Intervention: P3f component identified in faster responders
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: P3b component identified
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pmp component identified
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pnt component associated with left frontocentral nontarget positivity
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Responses of faster responders
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Responses of slower responders
Number of subjects: 10
Study: 7499063

Group type: EXPERIMENTAL
Intervention: CGRP infusion
Number of subjects: 16
Study: 1524277

Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg single dose
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg single dose
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg b.i.d. at steady state
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg b.i.d.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6350072

Group type: EXPERIMENTAL
Intervention: Tioconazole base 1% cream applied twice daily
Number of subjects: 61

Group type: COMPARATOR
Intervention: Econazole nitrate 1% cream applied twice daily
Number of subjects: 61
Study: 31206782

Group type: EXPERIMENTAL
Intervention: Exergame intervention
Number of subjects: 55
Study: 30323575

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (no therapeutic intervention)
Number of subjects: 74
Study: 26739729

Group type: EXPERIMENTAL
Intervention: Participative learning intervention
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: Peer-mentoring intervention
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: Combined intervention (peer-mentoring + participative learning)
Number of subjects: 1494

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1494
Study: 24384865

Group type: EXPERIMENTAL
Intervention: Rehydration with oral rehydration solution (ORS), average consumption of 2040 mL (range; 1800-2500 mL)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Dehydration
Number of subjects: 5
Study: 22375612

Group type: EXPERIMENTAL
Intervention: Exenatide twice daily plus sitagliptin and metformin (ADD group)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Exenatide twice daily plus placebo and metformin (SWITCH group)
Number of subjects: 255
Study: 20569728

Group type: EXPERIMENTAL
Intervention: Biventricular (BIV) antitachycardia pacing (ATP)
Number of subjects: 526

Group type: COMPARATOR
Intervention: Right ventricular (RV) antitachycardia pacing (ATP)
Number of subjects: 526
Study: 16480973

Group type: EXPERIMENTAL
Intervention: Higher perceptual load (increased numbers of search items or a harder discrimination vs. detection task)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lower perceptual load (not explicitly defined in the abstract)
Number of subjects: 0
Study: 15961357

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 microg (TPTD20)
Number of subjects: 801

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 801